Copalia HCT

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

l-amlodipina, valsartan, hydrochlorothiazide

Available from:

Novartis Europharm Limited

ATC code:

C09DX01

INN (International Name):

amlodipine, valsartan, hydrochlorothiazide

Therapeutic group:

Antagonisti ta 'Angiotensin II, kombinazzjonijiet, Aġenti li jaġixxu fuq is-sistema renin-anġjotensin, antagonisti ta' Angiotensin II u calcium channel blockers

Therapeutic area:

Pressjoni għolja

Therapeutic indications:

Trattament ta ' l-ipertensjoni essenzjali bħala terapija ta ' sostituzzjoni fil-pazjenti adulti l-pressjoni tad-demm tagħhom huwa kontrollat adegwatament dwar il-kombinazzjoni ta ' amlodipine, valsartan u idrochlorothiazide (HCT), meħuda bħala tliet formulazzjonijiet ta ' wieħed il-komponent jew bħala a doppju-komponent u formulazzjoni wieħed-komponent.

Product summary:

Revision: 24

Authorization status:

Awtorizzat

Authorization date:

2009-11-03

Patient Information leaflet

                                75
B. FULJETT TA’ TAGĦRIF
76
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
COPALIA HCT 5 MG/160 MG/12.5 MG PILLOLI MIKSIJIN B’RITA
COPALIA HCT 10 MG/160 MG/12.5 MG PILLOLI MIKSIJIN B’RITA
COPALIA HCT 5 MG/160 MG/25 MG PILLOLI MIKSIJIN B’RITA
COPALIA HCT 10 MG/160 MG/25 MG PILLOLI MIKSIJIN B’RITA
COPALIA HCT 10 MG/320 MG/25 MG PILLOLI MIKSIJIN B’RITA
amlodipine/valsartan/hydrochlorthiazide
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara anke jekk għandhom l-istess sinjali ta’ mard
bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Copalia HCT u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Copalia HCT
3.
Kif għandek tieħu Copalia HCT
4.
Effetti sekondarji possibbli
5.
Kif taħżen Copalia HCT
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU COPALIA HCT U GЋALXIEX JINTUŻA
Il-pilloli Copalia HCT fihom tliet sustanzi li jissejħu amlodipine,
valsartan u hydrochlorthiazide.
Dawn is-sustanzi kollha jgħinu sabiex tkun ikkontrollata l-pressjoni
għolja tad-demm.
−
Amlodipine huwa membru ta’ grupp ta’ sustanzi li jissejħu
“imblukkaturi tal-kanali tal- kalċju”.
Amlodipine jwaqqaf il-kalċju milli jidħol fil-ħajt ta’ ġewwa
tal-vini u dan ma jħallix lill-vini
tad-demm jingħafsu.
−
Valsartan huwa membru ta’ grupp ta’ sustanzi li jissejħu
“antagonisti tar-riċetturi ta’
anġjotensin II”. Anġjotensin II jiġi ffurmat mill-ġisem u
jġiegħel il-vini jingħafsu, u għalhekk
jgħolli l-pressjoni tad-demm. Valsartan jaħdem billi jimblokka
l-effet
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Copalia HCT 5 mg/160 mg/12.5 mg pilloli miksijin b’rita
Copalia HCT 10 mg/160 mg/12.5 mg pilloli miksijin b’rita
Copalia HCT 5 mg/160 mg/25 mg pilloli miksijin b’rita
Copalia HCT 10 mg/160 mg/25 mg pilloli miksijin b’rita
Copalia HCT 10 mg/320 mg/25 mg pilloli miksijin b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Copalia HCT 5 mg/160 mg/12.5 mg pilloli miksijin b’rita
Kull pillola miksija b’rita fiha 5 mg ta’ amlodipine (bħala
amlodipine besylate), 160 mg ta’ valsartan,
u 12.5 mg ta’ hydrochlorthiazide.
Copalia HCT 10 mg/160 mg/12.5 mg pilloli miksijin b’rita
Kull pillola miksija b’rita fiha 10 mg ta’ amlodipine (bħala
amlodipine besylate), 160 mg ta’ valsartan,
u 12.5 mg ta’ hydrochlorthiazide.
Copalia HCT 5 mg/160 mg/25 mg pilloli miksijin b’rita
Kull pillola miksija b’rita fiha 5 mg ta’ amlodipine (bħala
amlodipine besylate), 160 mg ta’ valsartan,
u 25 mg ta’ hydrochlorthiazide.
Copalia HCT 10 mg/160 mg/25 mg pilloli miksijin b’rita
Kull pillola miksija b’rita fiha 10 mg ta’ amlodipine (bħala
amlodipine besylate), 160 mg ta’ valsartan,
u 25 mg ta’ hydrochlorthiazide.
Copalia HCT 10 mg/320 mg/25 mg pilloli miksijin b’rita
Kull pillola miksija b’rita fiha 10 mg ta’ amlodipine (bħala
amlodipine besylate), 320 mg ta’ valsartan,
u 25 mg ta’ hydrochlorthiazide.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita (pillola)
Copalia HCT 5 mg/160 mg/12.5 mg pilloli miksijin b’rita
Pilloli bojod, b’forma ovali, konvessi fuq iż-żewġ naħat,
bix-xifer tasturat, imnaqqxin b’“NVR” fuq
naħa waħda u b’“VCL” fuq in-naħa l-oħra. Daqs
approssimattiv: 15 mm (tul) x 5.9 mm (wisa’).
Copalia HCT 10 mg/160 mg/12.5 mg pilloli miksijin b’rita
Pilloli sofor ċari, b’forma ovali, konvessi fuq iż-żewġ naħat,
bix-xifer tasturat, imnaqqxin b’“NVR”
fuq naħa waħda u b’“VDL” fuq in-naħa l-oħr
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 27-09-2023
Public Assessment Report Public Assessment Report Bulgarian 13-12-2013
Patient Information leaflet Patient Information leaflet Spanish 27-09-2023
Public Assessment Report Public Assessment Report Spanish 13-12-2013
Patient Information leaflet Patient Information leaflet Czech 27-09-2023
Public Assessment Report Public Assessment Report Czech 13-12-2013
Patient Information leaflet Patient Information leaflet Danish 27-09-2023
Public Assessment Report Public Assessment Report Danish 13-12-2013
Patient Information leaflet Patient Information leaflet German 27-09-2023
Public Assessment Report Public Assessment Report German 13-12-2013
Patient Information leaflet Patient Information leaflet Estonian 27-09-2023
Public Assessment Report Public Assessment Report Estonian 13-12-2013
Patient Information leaflet Patient Information leaflet Greek 27-09-2023
Public Assessment Report Public Assessment Report Greek 13-12-2013
Patient Information leaflet Patient Information leaflet English 27-09-2023
Public Assessment Report Public Assessment Report English 13-12-2013
Patient Information leaflet Patient Information leaflet French 27-09-2023
Public Assessment Report Public Assessment Report French 13-12-2013
Patient Information leaflet Patient Information leaflet Italian 27-09-2023
Public Assessment Report Public Assessment Report Italian 13-12-2013
Patient Information leaflet Patient Information leaflet Latvian 27-09-2023
Public Assessment Report Public Assessment Report Latvian 13-12-2013
Patient Information leaflet Patient Information leaflet Lithuanian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 27-09-2023
Public Assessment Report Public Assessment Report Lithuanian 13-12-2013
Patient Information leaflet Patient Information leaflet Hungarian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 27-09-2023
Public Assessment Report Public Assessment Report Hungarian 13-12-2013
Patient Information leaflet Patient Information leaflet Dutch 27-09-2023
Public Assessment Report Public Assessment Report Dutch 13-12-2013
Patient Information leaflet Patient Information leaflet Polish 27-09-2023
Public Assessment Report Public Assessment Report Polish 13-12-2013
Patient Information leaflet Patient Information leaflet Portuguese 27-09-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 27-09-2023
Public Assessment Report Public Assessment Report Portuguese 13-12-2013
Patient Information leaflet Patient Information leaflet Romanian 27-09-2023
Public Assessment Report Public Assessment Report Romanian 13-12-2013
Patient Information leaflet Patient Information leaflet Slovak 27-09-2023
Public Assessment Report Public Assessment Report Slovak 13-12-2013
Patient Information leaflet Patient Information leaflet Slovenian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 27-09-2023
Public Assessment Report Public Assessment Report Slovenian 13-12-2013
Patient Information leaflet Patient Information leaflet Finnish 27-09-2023
Public Assessment Report Public Assessment Report Finnish 13-12-2013
Patient Information leaflet Patient Information leaflet Swedish 27-09-2023
Public Assessment Report Public Assessment Report Swedish 13-12-2013
Patient Information leaflet Patient Information leaflet Norwegian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 27-09-2023
Patient Information leaflet Patient Information leaflet Icelandic 27-09-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 27-09-2023
Patient Information leaflet Patient Information leaflet Croatian 27-09-2023
Public Assessment Report Public Assessment Report Croatian 13-12-2013

View documents history